Case Report: Atypical pattern of pathologic response in cutaneous transdifferentiated melanoma with rhabdomyoblastic differentiation following neoadjuvant therapy - Scorecard - MDSpire
Advertisement
Case Report: Atypical pattern of pathologic response in cutaneous transdifferentiated melanoma with rhabdomyoblastic differentiation following neoadjuvant therapy
Clinical Scorecard: Case Study: Unusual Pathologic Response in Cutaneous Melanoma with Rhabdomyoblastic Differentiation Following Neoadjuvant Treatment
At a Glance
Category
Detail
Condition
Transdifferentiated melanoma with rhabdomyosarcomatous differentiation
Key Mechanisms
Phenotypic plasticity, immune escape, high tumor mutational burden
Target Population
Patients with resectable stage III and IV melanoma
Care Setting
Oncology, specifically in the context of neoadjuvant immunotherapy
Key Highlights
Rare variant of melanoma characterized by loss of melanocytic markers and aggressive behavior
Patient experienced immune-related hepatitis and aseptic meningitis during treatment
Post-treatment pathology showed complete regression of melanocytic component but viable rhabdomyoblastic component
Molecular profiling revealed NRAS Q61R and TERT promoter mutations, with implications for treatment resistance
Neoadjuvant immunotherapy is increasingly used in clinical practice for melanoma management
Guideline-Based Recommendations
Diagnosis
Integrated histopathological and molecular assessment for accurate diagnosis
Management
Neoadjuvant immunotherapy with ipilimumab and nivolumab for resectable melanoma, supported by recent clinical trials
Monitoring & Follow-up
Close oncologic surveillance post-treatment to assess for viable tumor components
Risks
Potential for immune-related adverse events such as hepatitis and meningitis
Patient & Prescribing Data
38-year-old male with a history of cutaneous melanoma
Neoadjuvant treatment led to mixed metabolic response, necessitating immunosuppressive therapy; specify imaging findings.
Clinical Best Practices
Characterize pathological responses in melanoma variants to tailor treatment strategies
Utilize biomarkers like IFNγ, PD-L1 expression, and tumor mutational burden for predictive insights in clinical practice
